A broad range of health effects in a cohort 2001; 45:222-237) 
We performed this study to actively survey adverse events in a defined medical staff cohort who were to be immunized in the context of routine military occupational medicine requirements.
Methods
Health care personnel stationed at Tripler Army Medical Center : I'AMCi and al Schofield Barracks Health Clinic. 15 miles away, who started the anthrax vaccine series between September 12 and October 16. 1998 . were enrolled in the project. TAMC is a 229-bed tertiary care hospital and ambulatory care center in Honolulu. Hawaii. Schofield Barracks Health Clinic is TAMC's largest primary care clinic, serving soldiers and families in the 25lh Infantry Division. All individuals traveling to or potentially deploying to countries determined by DOD's operational risk assessment lor exposure to weaponi/ed anthrax were immunized according to standard DOD policy. The dates of enrollment corresponded with the immunization of soldiers in the Korea Medical Augmentee Program, individuals who would deploy to Korea if war recurred.
All were immunized with AVA (BioPOfl Corporation. Lansing. MI) in accordance with DOD AVIP requirements and procedures. The only additional requirement was for the individual to complete a survey 1 to 2 weeks, or as close thereafter, after immunization. There were no individuals who requested not to be vaccinated. Strict patient confidentiality was maintained in administering, storing, and analyzing all surveys.
Vaccinees registered at the immunization clinic, were offered information regarding the anthrax vaccine, anil were interviewed to determine if they had contraindications (o immunization. Individuals were excluded from immunization if they had an active infection or acute illness, were pregnant, were receiving immunosupprcssive drugs, or had a serious adverse reaction to a previous anthrax vaccine.'
x Those who were medically cleared were immunized.
Participants were immunized according to the PDA-approved. AVA dosage schedule that stipulates subcutaneous administration of the vaccine at 0, 2. and 4 weeks and al 6. 12, and 18 months.
181 " Records of the immunization, including date, person authorizing immunization, and lot number, were recorded in the US Army's centralized Medical Occupational Data System according to standard DOD AVIP procedures to assure that the correct number and proper timing of subsequent doses occurred. Records were also stored in the automated Composite Health Care System that records immunization and other patient-oriented data at TAMC. 1 "
The survey of reported events after AVA immunization was approved by the Human Use Committee of the US Army Medical Research Institute of Infectious Diseases. Approval for the overall project, including the cohort comparison of reported health and wellness using a health risk appraisal instrument, and the cohort comparison of outpatient health visits and hospitalizations. was granted by the TAMC Department of Clinical Investigation. All procedures were conducted under federal rules for protection of research subjects' 1 "
and were without increased risks to the study subjects.
Survey of Symptoms, Severity, and Duration After Immunization Individuals completed a survey al least I week, and mosi often 2 weeks, after immunization. The survey instrument was adapted from a US Army Medical Research Institute of Infectious Diseases occupational health clinic template used to assess events after immunization. The survey asked explicitly about loss of appetite, headache, fatigue, muscle aches, joint aches, itching, nausea and/or vomiting, diarrhea, chills, shortness of breath, and fever. Individuals indicated severity using a symptom severity key: "none." "symptoms and signs can be ignored." "symptoms and signs affect activity but can perform anyway," "sv mploms and signs affect activity, but relieved by medication." and "symptoms and signs not relieved by medication, can't perform activities.'" Ifihey had any symptoms, they listed the duration, using a duration key: "less than 6 hours." "'7-24 hours." "25-72 hours." or '"greater than 72 hours." Additional space was provided for individuals to list other symptoms and provide comments. At the same time, using a sign-in rosier, we requested information whether they had an outpatient medical visit, were hospitalized, or missed one or more S-hour shifts of work.
After the first three immunizations, additional data were collected on localized, injection-site reactions using an additional survey questionnaire. Consequently, personnel reported these additional localized events retrospectively for the first three inoculations, approximately 6 months after the study began (ie, when they came in for their fourth immunization), and prospeclively thereafter. This survey included diameter of erythema, tenderness, itching at site, swelling below the elbow, and "presence of a lump or knot." We assessed severity of symptoms using a key identical to that of the original survey instrument.
Data were analyzed using Statistical Analysis Systems (SAS) software (SAS Institute. Cary. NC). Univariale analysis and logistic regression were performed to determine the association of reported symptoms with demographic characteristics. Statistical significance was designated at P < 0.05 (two tailed) and 957c confidence intervals.
Vaccine Adverse Event Reporting System Reports
In accordance with IX)D"s guidance on reporting VAERS. any individual who was hospitalized, had more than one lost duly day (.24 h or more) after anthrax immunization, or had an event suspected to have resulted from contamination oi a saccine lot was evaluated further. Medical records of these individuals were obtained, contact was made with their medical provider, and/or information was obtained directly from the patient to document the clinical details related lo the event. Except for events determined by a physician to be unrelated to immunization, the event was reported 10 the VAERS program, operated jointly by the FDA and the Centers for Disease Control and Prevention." 1 Also, healthcare providers were instructed and encouraged to complete VAERS reports if in their professional judgment any event after anthrax immunization was unexpected in nature or severity. In addition, individuals who were immunized could also selfreport directly to VAERS. The HEARS contains demo graphic information provided by the respondent regarding gender, marital status, highest educational level completed, annual total family income, and total number of children at home. Questions regarding reported aspects of health and wellness were selected from this 156-question survey based on their relevance to this project. These questions included self-reported general health: ever diagnosed with '"chronic headaches." "neurologic disease," "asthma," "muscle, joint or back problems." and "depression": self-reported mental health; experiencing surveydefined levels of stiess during the past 12 months: seeing a mental health professional during the past 12 months; experiencing serious personal or emotional problems during the past 12 months: feeling down, depressed or hopeless; bothered by little interest or pleasure in doing things: and satisfaction with life.
HEARS data from soldiers in the TAMC cohort immunized beginning in September 1998 were compared with data from anlhrax-unvaceinaled soldiers who also were al TAMC in September 1998. This was determined by linking Social Security numbers (SSNs) for the individuals who completed HEARS surveys to the Defense Medical Surveillance System (DMSS) database. DMSS provides a longitudinal record of demographic characteristics, periods of service, locations of assignment, medical events, and anthrax immunization records for all members of the active component of the US military. "' DMSS is maintained by the Army Medical Surveillance Activity (AMSA). US Army Center for Health Promotion and Preventive Medicine. Washington. DC. SSNs were used lor matching, then promptly deleted. Between May 1. 2000 and August 31, 2000. 3234 soldiers completed the HEARS survey. Three hundred and one soldiers belonged to the TAMC 601 cohort and 639 were in the unimmunized control group of soldiers stationed at TAMC in September 1998 who never received an anthrax immunization. Data analysis was performed at the Naval Health Research Center in San Diego. CA. to assure that, even without names, individuals could not be identified based on their responses, thus assuring strict confidentiality.
Data were analyzed using SAS statistical software. Univariate analysis using Chi-square (95% confidence interval, two-tailed) was performed to define cohort differences with regards to demographic characteristics and to compare responses between cohorts. Stratification was used to adjust for demographic differences between the groups.
Cohort Study of Outpatient Health Care Visits and Hospitalizations
The DMSS identified active duty soldiers stationed at TAMC on Oelober I. 1998. Outpatient visits and hospitalizations in the military health care system in this group from October I. 1998. through September 30. 2000. were evaluated. Up to eight outpatient International Classification of Diseases, Ninth Revision. Clinical Modification (ICD-9-CM) codes and up to four inpaticnt ICD-9-CM codes are recorded by the DMSS.
Three groups were identified: 1) 600 soldiers enrolled in (he TAMC survey cohort: 2) 225 soldiers who received an anthrax immunization 637 soldiers who were not immunized wilh anthrax vaccine before October I, 2000. the cutoff date for this study. These groups were then categorized into "pre-immunizaiion" and " hospilalizalions. as well as ICD-9-CM-bused diagnostic groups, between the pre-and post-immunization periods. Specific categories ol interest were musculoskclclul (ICI) 9-CM codes 710 739). mental (290-319), digestive (520-579). injury (800-999). and symptoms ill defined (780-799). Rale ratios were adjusted for age and gender by Poissou regression modeling using SAS' Genmod procedure." Strict confidentiality of medical information and records v.as maintained in accordance with standard AMSA procedures.
Results 600 soldiers and one Department of ihe Army civilian worker began the anthrax vaccine series between September 12 and October 13, 1998 al TAMC. The composition of I he TAMC 601 cohort, characterized by gender, rank, and age is shown in Table I .
Survey of Symptoms. Severity, and Duration After Immunization
Immunizations in ~~ 3069) were administered lo ihi^ cohort at TAMC. Of these. 2849 questionnaires (93%; fable 2) and 2734 sur vej s iS9'/f.) for local reactions (Table  3) were completed. Survey completion rates, defined as the number of surveys completed divided by 601 individuals, for questionnaires I and 2 are shown in Fig. I . During the 2-year survey period, enrollees dropped out because of pregnancy. medical exemptions, leaving the Army, and performing duly elsewhere. Some of these were temporary, for example, pregnancy, certain medical exemptions, and temporary duly elsewhere. Many individuals were transferred to other assignments, as a tour of duly outside the contiguous United Stales is generally 3 years. These individuals continued to receive the anthrax vaccine al their new location, hut iheir surveys were not collected at TAMC. Others retired, completed their military obli- Of 3060 immunizations administered at TAMC. the most common re ported post-ininiuni/alioii events from questionnaire I, in order of decreasing frequency, were muscle ache, fatigue, headache, and joint ache ( Table 2 ). Women in general had slightly higher rales for these reported events than men. The median duration for these reported events was 24 lo 72 hours, with no distinct difference by gender.
Reported localized events assessed in questionnaire 2 were common ( Table 3 ). The presence of a "lump or knot" was mosi often reported after immunization, followed by localized muscle soreness, localized itching, and erythema greater than 5 cm in diameter. The rales of reported muscle soreness decreased during ihe first five immunizations before slightly increasing with ihe sixth dose. I lie rates of the other reported localized events were similar alter each immunization. 6% of patients reported pain limbing motion of the elbow and sv.e ;uy ol ihe lowei ai in Gender was significantly correlated with reported localized events.
1 he rale ratio for women compared to men for report of any local reaction was 1.4 (95% confidence inter val: 1.3-1.5). Rale ralios were highesl for reported localized piui'itus (RR: 2.3; 95% CI: 2.1-2.5). followed On average, after each immunization. 3.9% of ihe men and 5.8% of the women repotted that they could not perform one or more of their normal duties temporarily because of an event. Muscle aches, followed in frequency by headaches, joint ache, and fatigue again were the most common reported events affecting performance o( duties (Table 4) . Rales of performance impairment overall were highest after the first immunization (6.09! male. 12.291 fc male), and decreased during the second immunization with reports primarily of muscle aches and joint itches. Observable trends by immunization dose thereafter were unremarkable.
VAERS Reports
There were five events reported to VAERS from ;i total of 306°-immunizations administered. The medical information is summarized as follows:
• A 35-year-old male developed myalgias, upper extremity motor weakness, and tremors beginning 4 days after his second immuniza tion. His serum ereatinine phosphokinase was above 1000 mg/dL. This condition resolved after treatment with prednisone and has not reclined. 
Self-Reported Health and Wellness at Completion of the Vaccine Series
The HEARS survey responses of the TAMC 601 cohort and llie tinimmunized cohort, both of whom completed this survey between May I and August 31. 2000. were compared. Characterization of the two groups by gender, age, marital status, education, and total annual household income, as reported in the HEARS survey, is shown in Table 5 .
Responses lo each question were not statistically different between the two groups {Table 6). Because of the variability in demographic characteristics between the cohorts, relative risks were subsequently compared stratifying the survey results individually by gender, age. marital status, education, and total annual household income. The only association that was remarkable in this comparison of 26 indicators and 13 demographic variables (within live demographic categories) was thai women in the immunized cohort were mure likely to report that their general health was "poor or fair" compared with the unimmunized cohort iRR •1A; 95% CI: 1.3-15.1). The report of poor or fair health occurred in six of General health as "Very Good to Excellent" Gene'al hcaith described as "Good" Gene'al heath describee as "Poc to rai. 91 women (6.6%) in the immunized oil:ut compared with four of 264 women (1.5%) in the non-immunized cohort. Otherwise, there were no notable trends or associations.
Cohort Study of Outpatient Health Care Visits and Hospitali7ations
Rate ratios comparing rates or outpatient visits and hospilali/aiions in the period before the first anthrax immunization (or no immunization) wilh the rate of outpalienl visits and hospitalizations in the period alter llv Inv m.nun:!/..I:;:'!, holh nr.iiljusted as well as adjusted for ace and gender are shown in Fig. 2 . The rate ratio for outpatient visits For mental hcaith was lower in the immunized versus unimmuni/ed cohorts and was statistically significant (RR: 0.76: 95* Cl: 0.7-0.9. unadjusted: RR: 0.82: 95% Cl: 0.8-0.9. adjusted). Otherwise, rale ratios were unremarkable.
We also compared rales of leaving active Annv service between the TAMC 601 cohort and the I 'A.VIC unimmunized cohort (group 3, methods) and noted that rates of discharge were 1.7 times higher in the non immunized control group compared to the TAMC 601 cohort. Numerators for these rates were defined as soldiers who voluntarily left the active Army, were separated due to medical or administrative causes, or retired.
Discussion
Assessments of four distinct health care outcomes were used 10 charac-;eri/e nou nl al advene events in 601 consecutive healthcare personnel immunized wilh AVA til TAMC. Shortterm outcomes were assessed using two survey questionnaires of selfreported events that occurred after AVA immunization and VAERS reports of more serious events temporally associated wilh AVA immunization. Longer-term outcomes of up to 2 years were assessed by comparing reported health information from a standardized heallh appraisal in slrianeni as well as rales of outpatient visits and hospitalizations in immunized and non-immunized soldiers.
Localized reactions, including erythema, local tenderness, subcutaneous nodules, and localized itching. were commonly reported and occurred more often in women than men. This is consistent wilh other surveys that evaluated events by gender."' , '" Systemic events, such as fatigue, headache, and arthralgias, were less commonly reported than localized events, consistent with other studies." -''"' M) and were reported more often in women than men.
21
' Events occasionally resulted in brief limitation of activities, which also occurred more common!} in women than men. The Institute of Medicine 28 concluded that the types of local and systemic reactions associated with AVA and the rates at which they were observed are comparable to those observed with other vaccines regularly administered to adults, such as diphtheria and tetanus inflammatory demyelinating disease may have had latent multiple sclerosis before immunization, but immunization may have facilitated unmasking the symptoms. All five cases were reported to the VAERS because the goal of the VAERS is to cast a wide net and capture any significant sentinel events that might he attributable to the anthrax vaccine.
1 ' ' These events can then he evaluated epidemiologically using population databases, such as DMSS. to determine the strength of association for these events in immunized and unimmunized cohorts and investigate a potential causal relationship. "
,N At present, only localized events reported to VAERS are known to he causally related to immunization with AVA.
Sell reported health and wellness indicators using the HEARS health risk appraisal instrument enabled us to compare another dimension of health outcomes between immunized and non-immunized soldiers. Evaluation of 26 key health indicators did not reveal any significant differences between immunized and non-immunized cohorts. Availability of information on age, gentler, education, and family income allowed us to investigate demographic subpopulaiions to determine if we could discern any significant difference in imported health between the immunized and non-immunized cohorts. The only statistically significant association in this entire analy sis. a report of poor or fair health occurred in six of 91 women (6.6%) in the immunized cohort compared with four of 264 women (1.5%) in the non-immunized cohort, may be due to a statistical anomaly with multiple comparisons using /' < 0.05 us a cutoff. The association, on the Other hand, may be valid, with immunization a confounder or surrogate lor deployability that is considered a greater challenge for women limn men. particularly those who have children.
We compared rales of outpatient visits and hospitalizations between immunized and non-immunized soldiers who were stationed at TAMC on 1 October 1W<S using ICD 9 CM diagnostic groups. In our analysis. i ale ratios for categories of outpatient visits and hospitalizations for immunized versus non-immunized TAMC soldier cohorts were unremarkable, even after adjusting for age and gender. Comparing diagnostic categories, only outpatient mental health visits were statistically significant (/' < 0.05) with rates lower in the immunized cohort.
The AMSA evaluates rates of outpatient visits and hospitalizations by ICD-9 CM diagnostic groups periodically to identify any populationbased trends in vaccine-related events. Events identified by VAERS or excess of outpatient visits or hospitalizations in a relevant diagnostic category would prompt an epidemiological analysis of specific disease entities using a population database, for example, the DMSS and Naval Health Research Center (NIIRC) databases.
To dale, no significant elevations have been identified, after adjusting for multiple comparisons.
The use of four distinct study designs in this analysis helped to balance limitations of each, while contributing their own inherent strengths. Active surveillance was used in evaluation of events occurring after immunization, which may account for higher rales of reported c\ cuts than studies using passive surveillance. 17 .28,34 Surveillance covered the entire scries of six immunizations in contrast to other population-based studies, but routine changeover in personnel in die active duty Army contributed significantly to dropout rates. A comparison of rates for soldiers leaving active A rim service in this cohort indicated that immunized soldiers were much less likely lo leave than unimmunized soldiers.
The surveys lacked a control group because a placebo group was considered unethical for individuals needing AVA to protect them from enemy use of weaponized anthrax. This could account in part for higher rates of reported side effects in surveys 26,28 compared with the only controlled trial done to evaluate anthrax vaccine side-effects." Individuals' reporting of events arc subject lo observational bias, as well as mis interpretation of the questionnaire. Muscle aches on die first questionnaire were designed lo identify sys temic complaints of myalgia, yet we learned well into the study that these were almost always interpreted as a localized reaction by those surveyed. The absence of a control group and biases associated with patient selfreports does not enable us lo accu rately quantify the attributable rate of adverse events. Although sensitivity is high for detecting acute events after immunization, particularly any serious ones, specificity is low due to itiisallrihulioii of events lo anthrax immunization. Nonetheless, surveys are useful for identifying trends and potentially serious, acute adverse events.
The VAERS analysis facilitated identification of potentially serious sentinel events, which could subsequently be evaluated using large population databases like DMSS. By itself. VAERS has limited utility due to concerns associated with variability of reporting, determination of significance, and interpreting whether events are related to the anthrax vaccine. 28 Only the report of a large localized reaction could be definitively attributed to AVA-immunization, and this event resolved without intervention.
The two-arm cohort study of reported health and wellness using a standardized health risk appraisal instrument was particularly valuable because the data were nested and were not biased by knowledge of its potential use in llus study by survey recipients. The use of a control group, as well as the ability to stratify using numerous relevant demo graphic variables, was an additional strength. Use of multiple comparisons, however, can reduce ihe level of specificity for detecting a statist!-cully significant association, unless the P value is reduced. A potential weakness, characteristic of this type of" survey, relates to the validity of responses provided by recipients and their uniformity in interpreting questions. This would be minimized if non-differential bias between cases and controls occurred.
The three-arm cohort study of outpatient visits and hospitalizations benefits from having a reasonable control group that can be adjusted for age and gender. Bias due to the healthy worker effect is potentially present. Availability of a relevant control group counters the problem noted using surveys that lack a control group in assessing attribution of adverse vaccine events resulting in outpatient visits and hospitalizations. Diagnostic categories and not individual diagnoses could be evaluated because of the statistical requirements with sample size. DMSS is currently using larger populations to evaluate both disease categories and specific diseases.^-^ Analysis of outpatient visits and hospitalizations would not accurately detect mild adverse events, although this is balanced by our utilization of postimmunization surveys.
It is important to study effects of AVA-immunization in other groups, as has been done."-* 08 ^ because of inherent uncertainties of generalizing reports from medical personnel to other population groups. A hospital staff cohort may display a potentially greater sensitivity for delecting post-immunization events, interpret events differently than the general public, has different occupational exposures, and has greater access to health care. Based on the aggregate analysis of studies there is no indication of serious adverse health effects at present.
A recent pilot study showed that intramuscular administration of AVA eliminated most of the injection site reactions noted with this vaccine. In addition, two doses of AVA administered 4 weeks apart were as imnuinoucnic as three doses over 4 weeks at peak.' ' The CDC is currently conducting a large pivotal study to confirm these results. Intramuscular administration and fewer doses of AVA, if shown to be safe and effective in this trial, would only improve the benefit/risk ratio.
The findings of this study support the relative reactogenieity of AVA immunization but do not reveal any serious adverse events or effects on health. This is consistent with other published studies.
I5 * 28 This strongly supports a benefit/risk ratio in favor of using AVA for IX)D service members, particularly those deployed to high threat areas. The set of studies reported here identified no rationale for delaying protection of service members deploying to high risk areas who face the threat of aerosolized anthrax.
